Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts

mTOR is a rational target in renal cell carcinoma (RCC) because of its role in disease progression. However, the effects of temsirolimus, the only first-generation mTOR inhibitor approved by the FDA for first-line treatment of metastatic RCC, on tumor reduction and progression-free survival are mini...

Full description

Saved in:
Bibliographic Details
Published in:Int J Cancer
Main Authors: Ingels, Alexandre, Zhao, Hongjuan, Thong, Alan E., Saar, Matthias, Valta, Maija P., Nolley, Rosalie, Santos, Jennifer, Peehl, Donna M.
Format: Artigo
Language:Inglês
Published: 2013
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4365782/
https://ncbi.nlm.nih.gov/pubmed/24243565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.28579
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items